Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Teva Pharmaceutical Industries ADR Representing One TEVA

Healthcare
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSE:TEVA)

Teva to Present at the Jefferies London Healthcare Conference

GlobeNewswire 13 days ago

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

GlobeNewswire November 6, 2024

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

GlobeNewswire November 1, 2024

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)

GlobeNewswire November 1, 2024

Teva Statement on European Commission Decision; Company to Appeal

GlobeNewswire October 31, 2024

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI(TM) (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

GlobeNewswire October 22, 2024

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

GlobeNewswire October 8, 2024

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

GlobeNewswire October 3, 2024

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

GlobeNewswire October 1, 2024
View More News ››

Opinion & Analysis (NYSE:TEVA)

Gilead, Teva, XPhyto - Global marketing potential

Stockhouse Editorial June 16, 2020

The ASX: investing in an emerging biotech frontier

The Life Sciences Report August 10, 2016

An ETF That Provides Shelter From Stormy Markets

Benzinga.com  September 3, 2015

Buy biotech when there's blood on the street: Pontifax's Ran Nussbaum

George S. Mack September 3, 2015

Teva's Deal-Making Spurs Inflows To Israel ETFs

Benzinga.com  August 3, 2015

ETFs For The Next Pharma Takeover Candidates

Benzinga.com  July 28, 2015
View More Opinion ››

Bullboard Posts (NYSE:TEVA)

Teva Announces Strong Growth in Second Quarter Revenues main

Breaking News: $TEVA Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and...
whytestocks - July 31, 2024

Teva Reports First Quarter 2024 Financial Results and Reaffi

News; $TEVA Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial OutlookFor an accessible version of this...
whytestocks - May 8, 2024

Teva Reports Growth in Fourth Quarter and Full Year 2023

Just In: $TEVA Teva Reports Growth in Fourth Quarter and Full Year 20232023 revenues of $15.8 billion reflect an increase of 7% in local...
whytestocks - January 31, 2024

Opiates

<< View Post To Watch Video >>
Joe455 - December 30, 2021

Back in...

Lost a bit on this a few years ago, but bought back in this week at levels below what I had sold at, largely to crystalize the loss. I...
Paddy902 - April 28, 2019

CHECKOUT AVE.V ON THE VENTURE.STRONG WEDGE PATTERN BREAKOUT

STRONG US NUMBERS GOING INTO DRILLING SEASON
Charts1 - November 6, 2017
View more Bullboard ››

International Lithium Corp.

International Lithium Corp.

International Lithium Corp. is a Canadian lithium exploration company. The Company's key metals are lithium (Li), copper (Cu) ...
View More »